Q1 Earnings Forecast for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Femasys in a research report issued to clients and investors on Tuesday, February 11th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.23) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. HC Wainwright also issued estimates for Femasys’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.14) EPS and FY2029 earnings at $0.01 EPS.

Separately, Chardan Capital cut their price objective on shares of Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Performance

Femasys stock opened at $1.32 on Thursday. The business has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.12. Femasys has a 12 month low of $0.86 and a 12 month high of $2.40. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94.

Femasys (NASDAQ:FEMY) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The company had revenue of $0.55 million during the quarter, compared to analysts’ expectations of $0.40 million.

Hedge Funds Weigh In On Femasys

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aljian Capital Management LLC purchased a new stake in shares of Femasys in the third quarter valued at approximately $27,000. XTX Topco Ltd lifted its holdings in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after acquiring an additional 18,004 shares during the period. Geode Capital Management LLC lifted its holdings in Femasys by 9.2% in the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Femasys during the 4th quarter worth $25,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.